Form 8-K · Current Report · Filed 2024-10-22
Danaher Reports Third Quarter 2024 Financial Results
Danaher Corporation reported financial results for the third quarter of 2024, showing a net earnings of $818 million, or $1.12 per diluted common share, with total revenues increasing by 3.0% year-over-year to $5.8 billion.
- Filer
- Danaher Corporation DHR · NYSE
- Filed
- Accession
- 0000313616-24-000223
- CIK
- 0000313616
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
Non-GAAP core revenue increased by 0.5%. The company anticipates a low-single-digit decline in non-GAAP core revenue for the fourth quarter and full year 2024. The earnings press release, along with supplementary financial information, is furnished as Exhibit 99.1.
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$272.09
Next session
-5.9%
Since filing
-28.3%
Latest close
$194.98
What happened, not what will happen — closing prices around the filing date.
Exhibits (1)
About Danaher Corporation
Danaher Corporation is a globally recognized science and technology company specializing in the development, design, and manufacturing of diverse industrial and healthcare products. With a primary focus on innovations in diagnostics, life sciences, dental, and environmental and applied solutions, Danaher serves a multitude of industries and market sectors. Its cutting-edge diagnostic equipment aids medical professionals in delivering precise healthcare, while its life sciences tools and technologies propel biomedical research and development. The company's environmental solutions also play a key role in enhancing water quality analysis and management. Headquartered in Washington, D.C., Danaher is renowned for its strong operational culture exemplified by the Danaher Business System (DBS), which emphasizes continuous improvement and sustainable innovation. This approach has solidified Danaher's presence and influence in both developing specialized solutions and improving efficiency across global markets. The company's strategic acquisitions and consistent focus on innovation have positioned it as a leader in delivering essential solutions that drive significant improvements for healthcare, research, and industrial clients.
Never miss another DHR filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.